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Abstract: Although discovered already in the middle of last
century, the bottromycins are a unique class of natural
products, and a real challenge for all kind of researchers
trying to get familiar with them. The structure elucidation
was a tour de force and last over 50 years. Synthetic
approaches were also painful and it was actually the first and
so far only synthesis which confirmed/revised the previously
proposed structures. Recent investigations on the biosyn-
thetic pathway indicate that the bottromycins belong to the
ribosomally synthesized and posttranslational modified pep-
tides, but that also the biosynthesis does not proceed along
the “usual way”. This review will cover the development of
bottromycin research from the beginning until today, with a
focus on synthetic studies, total synthesis and modifications.
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1. Introduction
The bottromycins are an interesting class of rather unusual
peptidic natural products, isolated already in the mid 1950s
from the fermentation broth of a Streptomyces species found in
the area of Bottrop, Germany. Streptomyces bottropensis
produced a “new sulfur-containing” compound with interesting
antibiotic activity toward Gram-positive pathogens.[1] It was
observed that this compound inhibits protein synthesis in vivo
and in vitro,[2] but the detailed mode of action was unclear for
a long time.[3]
1.1 Structure Elucidation
Even more difficult was the structure elucidation of the
bottromycins. First attempts to solve the structure were made
by Waisvisz et al. in 1957 who assigned an empirical formula
of C38H57-61N7O7-8S for their “new sulfur-containing
antibiotic”.[1] Acidic hydrolysis provided six ninhydrin-pos-
itive substances, while two of them could be identified as
glycine and valine. The other four components were unclear,
but it was obvious, that the bottromycins must be peptides.[4]
Mild alkaline hydrolysis provided a crystalline compound
(C37H57N7O7S) which showed no antibiotic activity. Interest-
ingly, the reaction with methanol under acidic conditions
resulted in a recreation of the biological activity. Other
alcohols gave also rise to similar active compounds. Obviously
bottromycin contains an ester functionality which is important
for the biological activity.[5] Upon acetylation of bottromycin,
e.g., with acetic anhydride two crystalline decomposition
products were obtained. One of these compounds was
identified as the dipeptide methyl ester A (Figure 1).[5]
In 1965 Nakamura et al. isolated closely related antibiotics
from the strain Streptomyces No. 3668-L2, which they called
bottromycin A and B.[6] Acidic hydrolysis provided a mixture
of all-(S)-configured amino acids containing 3-methyl-phenyl-
alanine (β-MePhe),[7] tert.-leucine (t-Leu), valine, β-(2-thiazol-
yl)-β-alanine (thia-β-Ala)[8] and glycine. Bottromycin A con-
tained cis-3-methylproline (β-MePro), while proline was
incorporated into bottromycin B.[3b] They postulated a linear
N-acylated iminohexapeptide structure (B), a proposal which
was revised after synthetic studies[9] as well as by nmr
spectroscopic investigations by Takita et al. in 1976, which
proposed a cyclic iminopeptide structure.[10] This proposal was
verified by Schipper (1983)[11] and Kaneda (1991),[12] based on
detailed nmr studies. According to them the bottromycins are
cyclic tetrapeptides (C), connected to a tripeptidic side chain
via an amidine structure. The different bottromycins differ
only in the substitution pattern of the proline. The absolute
configuration of all building blocks was finally determined by
a total synthesis by the groups of Sunazuka and Ōmura in
2009, indicating that the original postulated all-(S)-configu-
ration of the amino acids was wrong.[13] The C-terminal thia-β-
Ala is not (S)- but (R)-configured (D). Shortly thereafter,
Bugni et al. (2012) reported the structure and biosynthesis of
bottromycin D, a bottromycin A derivative where the valine in
the ring is replaced by an alanine.[14]
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In the same year, the three-dimensional structure was
described by Gouda et al. based on nmr data.[15] Obviously the
side chain with the three C-terminal amino acids folds back to
the tetrapeptide ring in such a way, that β-MePro and thia-β-
Ala are located on one side of the molecule, what might be
important for the binding toward the bacterial ribosome.
Therefore, modifications at this positions should have an
influence on the biological activity of bottromycins and
derivatives.
1.2 Biosynthesis
The structure of the bottromycins is quite unique, not only
because of the amidine moiety but also because of the high
number of unusual amino acids. Like the structure, also the
biosynthetic origin of the bottromycins was unclear for a long
time. With respect to the rather unusual structural features one
might assume synthesis via non-ribosomal peptide synthetases,
a widespread bacterial pathway, but also a ribosomal pathway
can’t be excluded.[16] Early biosynthetic studies in the Arigoni
group (1997) using isotope labeling experiments showed, that
the “additional” methyl groups (Pro, Phe, 2×Val) and on the
C-terminal thia-β-Ala were incorporated from methionine.[17]
The methylation occurs with retention of configuration and
can be explained by radical SAM mechanism.[18] In 2012, four
groups identified independently biosynthetic gene clusters
(BGCs) in four different Streptomyces species.[14,19] They
found that the BGCs encode for three radical SAM meth-
yltransferases and propose a ribosomal peptide synthesis with
subsequent posttranslational modifications, what is in agree-
ment with the early feeding studies. Although such posttransla-
tionally modified peptides (RiPPs)[16a] are widespread found in
nature, also from the biosynthetical point of view the bottro-
mycins are really unique. In general, RiPPs are formed from a
larger ribosomally synthesized precursor peptide, consisting of
a core peptide and a leader peptide, which is post-
translationally modified by tailoring enzymes. But the
bottromycins are the first RiPPs which are “born” without a
leader peptide. Very recently, Koehnke et al. investigated in
detail the enzymes involved in the biosynthetic pathway.[20]
2. Synthetic Approaches and Total Syntheses of
Bottromycins
Before going into the total syntheses of the bottromycins, the
syntheses of the building blocks, the unusual amino acids will
be discussed. While tert.-leucine is commercially available,
the other non-proteinogenic amino acids are not.
2.1 Syntheses of the Non-proteinogenic Amino Acids
2.1.1 (2S,3R)-3-Methylproline (β-MePro) and Derivatives
Uli Kazmaier studied chemistry at the University of Stuttgart where he obtained his PhD in 1990 while working with U.
Schmidt on the synthesis of bottromycins. Afterwards he joined the groups of M. T. Reetz (Marburg) and B. M. Trost
(Stanford) as postdoctoral fellow. In 1992, he moved to Heidelberg, starting his own scientific work under the
mentorship of G. Helmchen. In 2000, he received a Novartis Chemistry Lectureship and in 2001 an offer for a full
professorship at Saarland University.
Figure 1. Proposed and final structures of bottromycins.
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While bottromycin B contains a non-methylated proline in the
tetrapeptide ring, (2S,3R)-β-MePro is incorporated into bot-
tromycin A and D. A first stereospecific synthesis was
reported by Titouani et al. in 1980.[21] Key step was a
Hofmann-Löffler-Freitag reaction using (S)-allo-lle (1) as a
starting material (Scheme 1). Esterification and N-chlorination
provided amino acid derivative 2. Irradiation in sulfuric acid
generated the δ-chlorinated amino acids via radical intermedi-
ates. Cyclization gave access to the desired amino acid 3
without affecting the asymmetric centers of the starting
material. In an analogous fashion the (2S,3S)-stereoisomer was
accessible from (S)-Ile.
Herdeis et al. reported the syntheses of both, the (2S,3S)-
and the (2S,3R)-isomer of β-MePro from pyroglutaminol
derivate 4, a common building block for the synthesis of
protease inhibitors (Scheme 2).[22] 1,4-addition of Me2CuLi
gave rise to the trans-configured product in good yield and as
single stereoisomer.[23] To get also access to the required cis-
isomer, 5 was subjected to elimination and subsequent cata-
lytic hydrogenation of 6 from the least hindered face of the
double bond provided 7 as a single diastereomer which was
converted into 3 via standard operations.
Karoyan and Chassaing used a 5-exo trig cyclization
between a chelated zinc enolate formed from 8 and a non
activated double bond (Scheme 3).[24] The reaction proceeded
with chirality transfer from the chiral α-methylbenzyl group
onto the C-2 carbon, and a chair-like transition state resulted
in the formation of the cis-configured proline derivative 9.
Hydrolysis and catalytic hydrogenation provide proline ester
10, which was saponified to the free amino acid 3. This
approach allows also the introduction of other substituents
onto the β-position via coupling the zinc derivative 9 with
electrophiles.[25]
Kamenecka et al. developed a protocol starting from
commercially available 3-hydroxy-(S)-proline 11
(Scheme 4).[26] Esterification and N-tritylation provided hy-
droxyester 12 which was oxidized to β-ketoester 13 and
further converted into enol triflate 14. The regioselectivity of
enolate formation was surprising: obviously the sterically
demanding trityl protecting group protects the chiral α-carbon
from deprotonation. Enol triflate 14 could be subjected to a
wide range of palladium-catalyzed cross-coupling reactions
allowing modification at the β-position. Cleavage of the trityl
group and subsequent catalytic hydrogenation provided methyl
ester 15 in moderate diastereoselectivity.
A synthesis of enantiomerically pure 3 based on a stereo-
selective cuprate addition as a key step was reported by
Flamant-Robin et al.[27] Starting material was chiral oxazo-
lidine 16, easily accessible from Garner's aldehyde
(Scheme 5). 1,4-addition of Me2CuLi provided syn-17 exclu-
sively in high yield. Standard operations gave rise to amino
acid derivative 18, which was converted into 3.
Scheme 1. Synthesis of (2S,3R)-β-MePro (3) via Hofmann-Löffler-
Freitag reaction.
Scheme 2. Synthesis of (2S,3R)-β-MePro (3) via 1,4-addition/stereo-
selective hydrogenation.
Scheme 3. Synthesis of (2S,3R)-β-MePro (3) via chelate-enolate
cyclization.
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2.1.2 (2S)-3,3-Dimethylproline (β-Me2Pro) And Derivatives
3,3-Dimethyl-(2S)-proline (β-Me2Pro) is one of the unusual
amino acids found in bottromycin C. A first enantioselective
synthesis has been reported by Sharma and Lubell in 1996.[28]
The regioselective enolization of 4-oxo-proline derivative 19
followed by alkylation with different alkyl halides, was used
for the synthesis of a variety of proline derivatives (Scheme 6).
Enolization with 4 eq. KHMDS and alkylation with methyl
iodide provided 20 in excellent yield.
Subsequent reduction of the keto group and desoxygena-
tion via radical reduction of the corresponding xanthate 21
gave rise to protected proline 22. The 9-phenylfluorenyl
(PhFl) protecting group could be removed together with the
benzyl ether via hydrogenation using Pearlman's catalyst.
Hydrogenation in the presence of Boc2O provided N-Boc-
protected β-Me2Pro 23.
A synthesis of racemic β-Me2Pro was reported by Medina
et al. starting from N-protected pyrrolidinone 24
(Scheme 7).[29] The lactam was reduced with NaBH4 to the
hemiaminal. Its treatment with TsOH and MeOH and
subsequent reaction with TMSCN in the presence of Lewis
acid provided racemic nitrile 25. Simultaneous removal of the
N-protecting group and saponification of the nitrile gave
access to amino acid 26 which could be separated into the
enantiomers via chiral preparative HPLC.
Another interesting approach towards racemic β-Me2Pro
derivatives was reported by Bott et al (Scheme 8).[30] N-
substituted azetidines 27 were heated with ethyl diazoacetate
in the presence of Cu(acac)2. Via Stevens [1,2]-shift a ring
expansion occurred to the dimethylated proline 28. Unfor-
tunately, a separation of the enantiomer was not reported.
Scheme 4. Synthesis of (2S,3R)-β-MePro methyl ester (15) via Stille
coupling.
Scheme 5. Synthesis of (2S,3R)-β-MePro (3) via 1,4-addition/cycliza-
tion.
Scheme 6. Synthesis of Boc-(2S)-β-Me2Pro (23) via regioselective
alkylation.
Scheme 7. Synthesis of (2S)-β-Me2Pro (26) via preparative HPLC.
Scheme 8. Synthesis of rac-β-Me2Pro derivative (28) via carbene
insertion.
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2.1.3 (2S,3S)-3-Methylphenylalanine (β-MePhe) and
Derivatives
By far most investigations focused on the synthesis of this
unusual amino acid because it also appears in some other
natural products such as mannopeptimycin[31] or the isoleucyl-
t-RNA-synthetase inhibitor SB-203208.[32]
In connection with one of the first synthetic studies
towards bottromycins Kataoka et al. described the synthesis
and optical resolution of β-MePhe via condensation of racemic
1-bromo-1-phenylethane with acetaminomalonate
(Scheme 9).[33] Hydrolysis and decarboxylation of 29 provided
a racemic mixture of diastereomers of 30, which could be
separated by fractional crystallization of the N-benzoyl
derivatives. The pure diastereomers could be further separated
into the enantiomers by treating the Cbz-protected-derivatives
with quinine or quinidine. Thus, all four stereoisomers of 32
could be obtained in pure form.
Many attempts have been undertaken to separate the
stereoisomers more easily using modern chromatographic
techniques, e.g. via chiral stationary phases on HPLC,[34]
capillary electrophoresis[34b,35] or anion exchange chromato-
graphy.[36]
Ogawa et al. reported an enzymatic approach to (2S,3S)-β-
MePhe (Scheme 10).[37] The racemic N-benzoylated amino
acid 31 was converted into the N-carbamoyl-derivative 33,
which was subjected to enzymatic cleavage using D-Carba-
moylase. While only the (2R,3R)-amino acid was slowly
hydrolyzed, the remaining (2S,3S)-derivative was chemically
hydrolyzed to the free amino acid 34.
Tsuchihashi et al. reported the synthesis of (2S,3S)-β-
MePhe from (R)-(1-phenylethyl)malonate 36, which was
obtained via Michael addition of malonate onto chiral vinyl
sulfoxide 35 in a 8 :2 diastereomeric ratio. Fractional crystal-
lization provided pure 36 (Scheme 11).[38] Subsequent desul-
furylation and saponification provided (R)-malonic acid 37,
which was subjected to α-bromination. Thermal decarboxy-
lation provided crystalline carboxylic acid 38, which after
recrystallization was diastereomerically pure. Treatment with
aqueous NH3 finally provided the desired amino acid 34.
Dharanipragada et al. described the first asymmetric syn-
thesis of all four stereoisomers of β-MePhe (Scheme 12).[39]
Commercially available racemic 3-phenylbutyric acid [(�)-39]
Scheme 9. Synthesis of (2S,3S)-β-MePhe derivative (32) via crystal-
lization.
Scheme 10. Synthesis of (2S,3S)-β-MePhe (34) via enzymatic kinetic
resolution.
Scheme 11. Synthesis of (2S,3S)-β-MePhe (34) via Michael addition
to chiral sulfoxide 35.
Scheme 12. Synthesis of (2S,3S)-β-MePhe (34) using Evans-auxiliary.
Review
Isr. J. Chem. 2020, 60, 1–15 © 2020 The Authors. Israel Journal of Chemistry published by Wiley-VCH GmbH www.ijc.wiley-vch.de 5
These are not the final page numbers! ��
was resolved into its enantiomers via fractional crystallization
using (S)- and/or (R)-methylbenzylamine. Activation of the
enantiomerically pure carboxylic acid 39 as mixed anhydride
and coupling with the Evans-auxiliary[40] provided N-acylox-
azolidinone 40. Formation of the boron enolate 41 and
subsequent bromination and azide formation via SN2 displace-
ment gave rise to azide 42. Saponification allowed the
recovery of the chiral auxiliary and the azido acid formed was
reduced to the desired amino acid 34.
Another auxiliary-controlled approach was reported by
Fioravanti et al. using Oppolzer’s auxiliary (Scheme 13).[41]
Kinetically controlled deprotonation/silylation of 43 gave rise
to a (E)-silylketeneacetal preferentially,[42] which was sub-
jected to amination. Its irradiation in the presence of ethyl
azido formate provided 44 with moderate diastereoselectivity,
but the diastereomers could easily be separated via flash
chromatography. Hydrolysis under acidic conditions (6 N HCl)
allowed the cleavage and recoverage of the chiral auxiliary.[42]
The groups of Pericas and Rieva developed a protocol
using a Sharpless epoxidation as a stereo-controlling step
(Scheme 14).[43] Asymmetric epoxidation of cinnamyl alcohol
and regio- and stereospecific ring opening with a N-
nucleophile provided starting material 45. Selective protection
of the primary OH-functionality and conversion of the
secondary alcohol into the mesylate allowed the synthesis of
aziridine 46 under basic conditions. Regioselective opening of
the aziridine ring with Me2CuLi, cleavage of the silyl
protecting group and oxidation provided Boc-protected amino
acid 47. A similar approach was also applied for the synthesis
of the (2R,3R)-enantiomer.[44]
O'Donnell et al. reported an acyclic stereoselective boron
alkylation as a key step (Scheme 15).[45] The protocol involved
the reaction of an α-acetoxy derivative of the benzophenone
imine of tert-butyl glycinate 48 with a chiral boron reagent 49
in the presence of cinchona alkaloids and LiCl. Depending on
the alkaloid used, cinchonine (CnOH) or cinchonidine
(CdOH), both α-stereogenic centers could be generated. It was
assumed that the stereoselective protonation is controlled by
complexation of the enolate to the alkaloid and delivery of the
proton from the least hindered face.
The group of Turner developed a chemoenzymatic route
towards enantiomerically pure β-MePhe derivatives, based on
an oxidation-reduction sequence (Scheme 16).[46] A key feature
was the combination of an enantioselective amino acid oxidase
(AAO), which oxidizes the α-amino acid to the corresponding
imine, together with a non-selective reducing agent, such as
BH3 ·NH3, which effects reduction of the imine back to the
starting material. Since the (2R,3S)-diastereomer of β-MePhe
52 can easily be obtained by asymmetric hydrogenation of the
corresponding (Z)-dehydroamino acid 51 this protocol also
allows the enantioselective preparation of the (2S,3S)-stereo-
isomer 34.[47]
Doi et al. reported a phase transfer-catalyzed alkylation of
glycinate Schiff base 53 with racemic 1-bromo-1-phenylethan
(2 equiv) under the influence of chiral quaternary ammonium
bromide 54 and 18-crown-6 (Scheme 17).[48]
Scheme 13. Synthesis of (2S,3S)-β-MePhe derivative 45 using Op-
polzer’s auxiliary.
Scheme 14. Synthesis of (2S,3S)-β-MePhe derivative 45 via Sharpless
epoxidation.
Scheme 15. Synthesis of (2S,3S)-β-MePhe derivative 50 via stereo-
selective protonation.
Scheme 16. Synthesis of (2S,3S)-β-MePhe 34 via enzymatic oxida-
tion/reduction.
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The chiral phase transfer catalyst can precisely discri-
minate not only the enantiofaces of the enolate but also the
central chirality of the halide during the C  C-bond formation.
Kinetic resolution provides the (2R,3S)-isomer of 50 in high
yield, enantio- and diastereoselectivity. Replacing the imine by
a N-benzoyl group (55) allowed the epimerization of the α-
stereogenic center via deprotonation/protonation.
Zhang. et al. described the application of a palladium-
catalyzed functionalization of C(sp3)  H bonds in the synthesis
of β-branched amino acids (Scheme 18). Using 8-aminoquino-
line (AQ) as a directing group N-phthaloyl- (Phth-) protected
Phe 56 was converted into fully protected β-MePhe derivative
57 in good yield and diastereoselectivity. The N-Phth group
could be deprotected with ethylendiamine and reaction with
TfN3 gave access to azide 58. Activation of the directing
amide group with Boc2O and subsequent treatment with
LiOH/H2O2 provided azido acid 59, which on hydrogenation
and Boc-protection delivered 47.
2.1.4 (S)- and (R)-3-(Thiazol-2-yl)-β-alanine (Thia-β-Ala)
The C-terminal unusual thiazolyl amino acid was the last one
whose configuration was determined. It required the total
synthesis of the bottromycins to establish it definitely. The
problems arose from the structure elucidation of bottromycin.
By hydrolysis of the natural product with conc. HCl Waiswisz
et al. obtained a “sulfur-containing amino acid”, unfortunately
showing no optical activity.[49] On the other hand, later on,
Umezawa's group obtained an optically active amino acid
([α]18D: +9) by hydrolyzing the antibiotic with acetic
anhydride.[3b]
To determine the structure of the C-terminal amino acid
Waiswisz prepared racemic thia-β-Ala 60 by addition of
hydroxylamine towards β-2-thiazolacrylic acid, which was
obtained by standard reactions (Scheme 19). Attempts to
increase the yield failed, and the addition of NH3 instead of
NH2OH resulted in the formation of the α-amino acid.[8]
Seto et al. tried to obtain optically active (S)-60 starting
from (S)-aspartic acid (Scheme 20).[8] The β-methyl aspartate
was obtained with SOCl2/MeOH, and after Phth-protection the
amide was formed via the mixed anhydride method. Stirring
with P4S10 at room temperature in dioxane generated thioamide
61, which was found to be unstable on silica gel. Thiazole
formation was performed by condensation of 61 with
bromoacetaldehyde or the corresponding acetal. Unfortunately,
Scheme 17. Synthesis of protected (2S,3S)-β-MePhe 55 under asym-
metric phase transfer conditions.
Scheme 18. Synthesis of (2S,3S)-β-MePhe derivatives 47 and 59 via
C  H functionalization.
Scheme 19. Synthesis of racemic thia-β-Ala 60.
Scheme 20. Synthesis of enantiomerically pure (+)-thia-β-Ala 60 via
crystallization.
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also the Phth-protected thia-β-Ala ester 62 was optically
inactive. In an analogous way the corresponding N-Cbz-
derivative could be obtained, also in racemic form. Obviously,
complete epimerization occurred in the thiazole formation
step. The racemic amino acid 63, however, could be resolved
into its antipodes by treating the Phth-derivative with brucine.
Hydrazinolysis of 63 gave access to the optically active
(+)-60, but with [α]17D: +22,4. The optical rotation was much
higher than the value reported by Umezawa. Obviously
through their hydrolysis, also some epimerization occurred.
Thus, the (+)-amino acid 60, the constituent of bottromycin,
was isolated in pure form. It was postulated to belong to the
(S)-series based on optical rotatory dispersion (ORD). The
thia-β-Ala derivatives prepared also lost their activity on
heating to reflux in 6 N HCl for 8 h, while the same
compounds were stable at room temperature or under slightly
basic conditions.
The only so far enantioselective synthesis of enantio-
merically pure (S)- and (R)-thia-β-Ala was reported by the
groups of Sunazuka and Ōmura (Scheme 21).[13] They took
advantage of the chiral sulfinamide chemistry developed by
Davis and Ellman.[50] Condensation of (S)-p-toluene sulfin-
amide 64 with 2-formylthiazole 65 provided sulfinimine 66 in
excellent yield. The subsequent Mannich reaction with allyl
methyl malonate gave access to 67 as a 1 :1 diastereomeric
mixture. Palladium-catalyzed decarboxylation removed the
epimeric stereogenic center and methyl ester 68 was obtained
as a single diastereomer. Removal of the sulfinyl group
afforded (+)-69 in quantitative yield. X-ray structure analysis
determined the absolute configuration to be (R). The opposite
(S)-enantiomer was obtained in an analogous fashion from (R)
sulfonamide 70.
2.2 Synthetic Studies towards Bottromycins
Because most structure proposals for the bottromycins were
wrong for a long time, it is not surprisingly that so far only
one total synthesis exists,[13,51] which also confirmed that the
C-terminal thia-β-Ala is (R)-configured and not (S) as origi-
nally reported. Therefore, early synthetic work could not be
successful because it was based on wrong assumptions, but it
focused on the synthesis of the partial structure of this rather
unique peptide. The first investigations were reported by
Yamada et al. already in 1977.[52] Their synthetic route was
based on the linear hexapeptide 71 proposed by Nakamura
et al. (Figure 2)[3b,c,6]
Yamada et al. focused on the formation of the central
amidine unit. Several amidines were prepared by condensation
of protected amino acid imido esters with amino acid esters
(Scheme 22).[53] Although, the desired amidine 72 could be
obtained without problems, it was impossible to prolong the
dipeptides at the C-terminus.
On activation, or even on standing under basic conditions,
cyclization to the corresponding imidazolone 73 was observed.
Therefore, they tried to generate the amidine unit of 76 by
coupling two model tripeptide fragments, the tripeptide imido
ester 74 and tripeptide 75 (scheme 23).[53] But interestingly, the
pKa-values of all synthesized amidines (pKa~9,3) were around
Scheme 21. Asymmetric synthesis of enantiomerically pure (+)-thia-
β-Ala-OMe 69.
Figure 2. Structure of bottromycin (71) according to Nakamura et al.
Scheme 22. Formation of amidine 72 and imidazolone 73.
Scheme 23. Formation of model amidine 76.
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1 pKa higher than in the natural product (~8.2), a first
indication that the structure proposal might be not correct.
Based on the revised structures by Schipper[11] and
Kaneda,[12] proposing a cyclic tetrapeptide with a tripeptide
chain connected via an unusual amidine moiety, Kazmaier
et al. focused on the synthesis of the corresponding peptide
ring and the highly substituted amidine.[54] Key step of their
approach was an Ugi-reaction using a protected thioamino
acid and NH3 as amine compound (Scheme 24). Although, Ugi
reactions with NH3 are often critical, giving a range of side
products, with sterically demanding aldehydes good results
were obtained.[55] With thiocarboxylic acids this approach
allows the synthesis of endothiopeptides.[56] With isocyanoace-
tate the linear tripeptide 77 could be obtained, which was
prolonged to the desired tetrapeptide 78 under standard
conditions. Attempts to cyclize 78 or to connect the side chain
via peptide coupling failed, because the thioamide underwent
cyclization to the thiazolinone 79, comparable to the imidazo-
lone formation reported by Yamada.[53]
In parallel, to figure out if amidine formation is possible
between sterically demanding amino acids thiopeptide 80 was
synthesized in an analogous fashion (Scheme 25). Because
attempts to couple 80 directly with amines failed, the
thioamide was converted into the corresponding thioimidoester
81, which could be reacted with valine methyl ester to 82 in
the presence of Hg(OOCCF3)2. The diastereomers formed
could be separated by flash chromatography, but unfortunately
this protocol could not be applied to endothiopeptide 77.
This caused a change in the strategy, replacing the
intermolecular amidine formation via an intramolecular one by
using the isocyanide of t-Leu-OMe (Scheme 26). The endo-
thiopeptide 83 was obtained in high yield and could be
prolonged on the N-terminus. S-Methylation and cyclization in
the presence of Hg(OOCCF3)2 gave access to cyclic amidine
84.
The amidine formation as key step was also investigated in
detail by Ōmura and Sunazuka et al. during their synthesis of
bottromycin A and B (Scheme 27).[51] They investigated the
reaction of thioamide 85 with the tripeptide side chain 86.
While no reaction was observed in THF using NEt3 as a base,
in the presence of Hg(OAc)2 unfortunately not the desired
amidine 87 was obtained but the amide 88. Better results were
Scheme 24. Synthesis of endothiopeptides via Ugi reaction.
Scheme 25. Synthesis of amidine 82 via Ugi reaction Scheme 26. Synthesis of cyclic amidine 84 via Ugi reaction.
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obtained with HgCl2 and Hg(OTf)2 as Lewis acids, and finally
2,6-lutidine as base in acetonitrile was the method of choice.
The same groups also preformed degradation studies of
bottromycin obtained by fermentation (Scheme 28).[57] They
subjected bottromycin A to pyrolysis in MeOH at 130 °C,
resulting in a cleavage of the tripeptide side chain. Besides
dipeptide 89 also a cyclic byproduct 90 was obtained as a
diastereomeric mixture. Obviously, the epimerization of the t-
Leu in the side chain occurred via the enol-form of imidazo-
lone 90. This could finally explain why the t-Leu obtained by
total hydrolysis of the bottromycin has a lower optical rotation
than synthetic enantiopure amino acid. Reduction of the
natural product under mild conditions provided alcohol 91,
which could be used to investigate cyclization conditions.
Dipeptide 89 was also used to determine the configuration
of the configurational labile amino acid thia-β-Ala (69).[8] Both
enantiomers were synthesized via the sulfinamide protocol
(Scheme 21) and subsequently coupled with azido-MePhe 59
(Scheme 29). Reduction of the azido group of 92 provided the
two diastereomeric dipeptides 89. Comparison of their 1H
NMR spectra with the spectrum of 89 obtained via pyrolysis
clearly indicated that the (R)-isomer is incorporated into the
bottromycins and that the original structure proposal (S) was
wrong. Coupling of 89 with Boc-(S)-t-Leu and subsequent
Boc-cleavage provided tripeptide 86, which was used in the
amidine formation experiments (Scheme 27).
2.3 Total Syntheses of Bottromycin and Analogous
Based on their own synthetic studies and with all building
blocks in hand Sunazuka and Ōmura et al. developed the first
and so far only complete total synthesis of bottromycin
(Scheme 30).[13,51] To extend the peptide chain, the Phth-group
of amidine 87 was removed and the free amine was coupled
with Boc-(S)-Val. Further prolongation gave rise to hexapep-
tide 93 which was subjected to desilylation and oxidation.
These last two steps should be carried out on stage of the
hexapeptide. Attempts to oxidize tetrapeptide 87 resulted in
the formation of a diketopiperazine. The oxidation was the
most critical step due to the nucleophilicity of the internal
amidine. Thus all oxidation methods proceeding via an
aldehyde intermediate failed, because this aldehyde was
trapped by the amidine forming an imidazole. Only Jones
oxidation was successful, providing an acceptable yield of the
desired carboxylic acid 94. The amidine also caused troubles
in the final macrocyclization step, and the best results were
obtained using EDCI/DIPEA in CH2Cl2, although here the
yield of bottromycin was only moderate. This protocol was
also used to generate some derivatives missing some β-methyl
groups, such as bottromycin B2 (Pro instead of MePro), or
derivatives where β-MePhe was replaced by Phe [Phe  BotA2
(95), PheBotB2 (96)]. Their NMR spectra were rather
Scheme 27. Synthesis of linear amidine 87.
Scheme 28. Degradation of bottromycin A2. Scheme 29. Synthesis of tripeptide side chain 86.
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complicated (existence of conformers), what suggests that the
methyl group of the β-MePhe is important for the three-
dimensional structure of the bottromycins.
It was known from the early saponification experiments[5]
that the methyl ester of the thia-β-Ala has a significant effect
on the biological activity of the bottromycins in vitro and
in vitro.[58] Therefore, Sunazuka and Ōmura also considered
the synthesis of a bottromycin derivative missing the C-
terminal amino acid, allowing modifications at this position in
the last step by coupling a wide range of amines to the
truncated hexapeptide.
Although this is a highly interesting approach, it was not
as trivial as it looked like. Azido-MePhe 59 was converted
into the corresponding benzyl ester and after reduction of the
azide coupled to Boc-(S)-t-Leu (Scheme 31).
The dipeptide 97 was incorporated into bottromycin
derivative 98 according to scheme 30. The benzyl ester could
be cleaved easily to the carboxylic acid, the key intermediate
for the synthesis of analogous. To proof the concept, the acid
was coupled with (R)-thia-β-Ala [(+)-69] to the original
natural product. The reaction proceeded smoothly, but
bottromycin A2 was only a side product. The major product
was derivative 99, containing an imidazole on the tetrapeptide
ring.
Control experiments suggested that on activation of the
carboxylic acid (100) attack of the adjacent amide bond
occurs, generating an oxazolinone 101, which is attacked by
the amidine under formation of the imidazole (Scheme 32).
The free carboxylic acid is activated again to 102, which
finally undergoes the amide bond formation to 99. So far,
HATU as coupling reagent gave the best yields for the
bottromycin A2 analogs 103 and was used for the incorporated
of a range of amines, but the corresponding imidazole was the
main product in all cases.
Further bottromycin derivatives were obtained by saponi-
fication of the natural product at the C-terminus and coupling
the free acid with suitable nucleophiles. Miller et al. could
show that some amide derivatives show better activity against
Staph. aureus in mice than the natural product.[59] Researcher
at AiCuris used this approach for the synthesis of “Weinreb-
amide”-type amides by reaction with linear or cyclic N,O-
dialkylhydroxylamines.[60] The groups of Ōmura and Sunazuka
synthesized a range of different derivatives via the correspond-
Scheme 30. Total synthesis of bottromycin A2.
Scheme 31. Variable synthesis of bottromycin A2.
Scheme 32. Formation of side product 99.
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ing hydrazide 103 as common intermediate (Scheme 33).[58]
Nitrosation of 103 gave rise to acyl azide 104 as an active
intermediate which could be coupled with a range of amines to
the corresponding amides 105. Application of mono Boc-
protected piperazine allowed further modification by replacing
the Boc-protecting group of 106. On the other hand, heating
the acyl azide to 60 °C resulted in a Curtius rearrangement
giving rise to an isocyanate 107, which on treatment with
amines provided ureas 108. Reacting 104 with thiols gave rise
to thioesters such as 109 which could be subjected to
palladium-catalyzed cross couplings with organozinc reagents
generating ketones 110.
3. SAR Studies of Bottromycins and Derivatives
First biological data for the bottromycins A–C were reported
by Nakamura et al.[3c] They determined the minimal growth
inhibitory concentrations (MIC) towards a wide range of
bacterial strains. The bottromycins showed strong inhibition
against Staphylococcus aureus, Bacillus subtilis and Mycobac-
teria in a low or even sub-micromolar range. Although highly
active in vitro, the bottromycins show no good in vivo
efficiency because of their instability in oral and parenteral
administration,[61] mainly because of the lability of the methyl
ester under physiological conditions.[58] The bottromycin acid
is more or less inactive. Therefore, Miller et al. prepared a
range of amide derivatives and compared their in vitro and
in vivo activity towards Staph. aureus.[59] Most compounds
were active, but the primary and secondary amides were less
active than the esters in vitro, but more active in vivo. Similar
observations were made with the Weinreb amides of the
AiCuris team.[60]
By far the most detailled SAR studies were reported by
Ōmura and Sunazuka. A wide range of different derivatives
were prepared from bottromycins obtained by fermentation
(Scheme 33), but they also investigated some desmethyl
derivatives, obtained by total synthesis (according to
Scheme 30). The results of the SAR studies are summarized
schematically in Figure 3.
The unusual methylation pattern has a significant effect on
the bioactivity towards Staph. aureus. Bottromycin D, where
the valine is replaced by a alanine was half as active as
bottromycin A,[3c] while bottromycin B, missing the methyl
group at the proline was 4-fold less active. Bottromycin C, the
dimethylated analogue was comparable active as bottromycin
A. The β-methyl group on the Phe seems to be essential, its
removal causes a dramatic drop in activity. Obviously this
methyl group influences the conformation of the side chain
and controls the three-dimensional structure of the whole
molecule, an assumption which is supported by 1H NMR.[13,51]
Linear peptides do not show significant activity, probably due
to a wrong three dimensional conformation, clearly indicating
that the cyclic peptide ring is essential.[51] Also no activity is
observed for derivatives with a COOH-group at the C-
terminus, or if the thia-β-Ala is missing completely. This
might be caused by a drop in the hydrophobicity. Interestingly,
incorporating the opposite (S)-isomer of thia-β-Ala has almost
no effect on the activity. The thia-β-Ala is not essential at all
for the activity, derivatives missing the acetate side chain or
the thiazole unit are only slightly less active. Obviously only
the amide functionality is necessary for good activities. The
moderate in vivo activity of the ester in the natural products
probably results from its low hydrolytic stability under
physiological conditions and its cleavage towards the almost
Scheme 33. Synthesis of bottromycin A2-analogs via hydrazide 103. Figure 3. Summary of SAR for bottromycin derivatives.
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inactive carboxylic acid. Although significant less active
in vitro, better in vivo stabilities are observed for secondary
aliphatic amides, while aromatic and tertiary amides as well as
those with basic side chains are almost inactive.[59] Piperazino
derivatives 106 and ureas 108 exhibit 4- to 32-fold weaker
activity in vitro, but better stability.[58] Thioesters such as 109
are significantly more active than bottromycin A, but due to
their great reactivity completely unstable e. g. in mouse
plasma. Ketones 110 which cannot undergo hydrolysis are
perfect stable and show activities comparable to bottromycin
A2 and vancomycin, but are also active against vancomycin
resistant strains.
4. Summary
Although isolated and described already 65 years ago the
bottromycins developed to a “nightmare” and a real challenge
for scientists of almost all fields of natural product science.
Even modern nmr techniques, developed during time, were not
able to solve the structure of the bottromycins correctly. Total
synthesis was required in order to determine the configuration
of the last stereogenic center. From the first synthetic studies
to the final total synthesis it took more than 50 years, until all
obstacles could be abolished.
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